

From: noreply@pharmacy.ohio.gov
To: MedicalMarijuana@med.ohio.gov
Subject: Condition Petition for Kevin Finisterre
Date: Monday, November 16, 2020 12:58:58 PM
Attachments: [studies.pdf](#)
[studies.pdf](#)
[studies.pdf](#)
[studies.pdf](#)

This message was sent from the Condition page on medicalmarijuana.ohio.gov.

Box was check regarding file size being too large to upload. Action needed!

Name: Kevin Finisterre
Address: 2271 Sutter pkwy, dublin, OH, 43016
Phone: (614) 209-6737
Email: kevinfinisterre@icloud.com

Specific Disease or Condition:

ADHD, Autism in Children recognized as Emotional Seizure due to their neurological linkages.

Information from experts who specialize in the disease or condition.

It is ridiculous that you make us fill these forms out when you know darn well you can go to NIH.gov among other places to find all of the evidence you need. And you limit space! The Presence of Comorbid ADHD and Anxiety Symptoms in Autism Spectrum Disorder: Clinical Presentation and Predictors <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306461/>
Examining autistic traits in children with ADHD: Does the Autism Spectrum Extend to ADHD? <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123401>

Relevant medical or scientific evidence pertaining to the disease or condition.

500 character max is a disservice to those folks in need. "MUST be a PDF file", you guys are trying HARD to exclude people here. It is sad.

- [studies.pdf](#)

Consideration of whether conventional medical therapies are insufficient to treat or alleviate the disease or condition.

Please read NIH studies....

- [studies.pdf](#)

Evidence supporting the use of medical marijuana to treat or alleviate the disease or condition, including journal articles, peer-reviewed studies, and other types of medical or scientific documentation.

PLEASE read NIH studies and stop playing games with the populace.

- [studies.pdf](#)

Letters of support provided by physicians with knowledge of the disease or condition. This may include a letter provided by the physician treating the petitioner, if applicable.

You guys are making a mockery of this process.... I started to fill this out with some serious hope, then go through it realizing you are completely gaslighting us. Do better. It wasn't even worth my time to TRY and fill out the factual information I have on hand because it is clear from this form that it will not be taken seriously.

- studies.pdf

General references:

Beside Oneself with Rage: The Doubled Self as Metaphor in a Narrative of Brain Injury with Emotional Dysregulation <https://link.springer.com/article/10.1007/s10912-018-9546-9>

Peaks and Troughs, Uneven Medication Coverage & ADHD. https://chadd.org/wp-content/uploads/2018/06/ATTN_Fall_17_PEAKS.pdf

Israeli studies:

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

<https://pubmed.ncbi.nlm.nih.gov/26800377/>

Cannabinoids for Behavioral Problems in Children With ASD (CBA)

<https://clinicaltrials.gov/ct2/show/NCT02956226>

Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study (P3.318)

https://n.neurology.org/content/90/15_Supplement/P3.318

Pharmaceutical CBD, and Medical Cannabis Reference list:

Artisanal CBD not as effective as pharmaceutical CBD for reducing seizures <https://www.sciencedaily.com/releases/2020/02/20200227160545.htm>

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000160/>

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial

<https://pubmed.ncbi.nlm.nih.gov/28576350/>

Cannabidiol (CBD) – what we know and what we don't <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>

Examining cannabidiol use in children [https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476](https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children)

Cannabinoids in Pediatrics [https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/)

Cannabinoids in Pediatrics <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/>

Pediatric cannabinoid Dosing Guidelines

<http://www.theroc.us/images/PediatricGuidelines.pdf>

"In general, the dose of CBD for a child is about 2.5 to 10 mg depending on their age, size, and symptom severity."

<https://dailycbd.com/en/cbd-children/>

Guanfacine Reference list:

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

<https://clinicaltrials.gov/ct2/show/NCT02048241>

Guanfacine in children with autism and/or intellectual disabilities

<https://pubmed.ncbi.nlm.nih.gov/18552703/>

Managing disruptive behavior in autism-spectrum disorder with guanfacine

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158025/>

Hallucinations associated with initiation of Guanfacine

[https://www.jaacap.org/article/S0890-8567\(09\)62120-1/pdf](https://www.jaacap.org/article/S0890-8567(09)62120-1/pdf)

General references:

Beside Oneself with Rage: The Doubled Self as Metaphor in a Narrative of Brain Injury with Emotional Dysregulation <https://link.springer.com/article/10.1007/s10912-018-9546-9>

Peaks and Troughs, Uneven Medication Coverage & ADHD. https://chadd.org/wp-content/uploads/2018/06/ATTN_Fall_17_PEAKS.pdf

Israeli studies:

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

<https://pubmed.ncbi.nlm.nih.gov/26800377/>

Cannabinoids for Behavioral Problems in Children With ASD (CBA)

<https://clinicaltrials.gov/ct2/show/NCT02956226>

Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study (P3.318)

https://n.neurology.org/content/90/15_Supplement/P3.318

Pharmaceutical CBD, and Medical Cannabis Reference list:

Artisanal CBD not as effective as pharmaceutical CBD for reducing seizures <https://www.sciencedaily.com/releases/2020/02/20200227160545.htm>

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000160/>

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial

<https://pubmed.ncbi.nlm.nih.gov/28576350/>

Cannabidiol (CBD) – what we know and what we don't <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>

Examining cannabidiol use in children [https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476](https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children)

Cannabinoids in Pediatrics [https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/)

Cannabinoids in Pediatrics <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/>

Pediatric cannabinoid Dosing Guidelines

<http://www.theroc.us/images/PediatricGuidelines.pdf>

"In general, the dose of CBD for a child is about 2.5 to 10 mg depending on their age, size, and symptom severity."

<https://dailycbd.com/en/cbd-children/>

Guanfacine Reference list:

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

<https://clinicaltrials.gov/ct2/show/NCT02048241>

Guanfacine in children with autism and/or intellectual disabilities

<https://pubmed.ncbi.nlm.nih.gov/18552703/>

Managing disruptive behavior in autism-spectrum disorder with guanfacine

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158025/>

Hallucinations associated with initiation of Guanfacine

[https://www.jaacap.org/article/S0890-8567\(09\)62120-1/pdf](https://www.jaacap.org/article/S0890-8567(09)62120-1/pdf)

General references:

Beside Oneself with Rage: The Doubled Self as Metaphor in a Narrative of Brain Injury with Emotional Dysregulation <https://link.springer.com/article/10.1007/s10912-018-9546-9>

Peaks and Troughs, Uneven Medication Coverage & ADHD. https://chadd.org/wp-content/uploads/2018/06/ATTN_Fall_17_PEAKS.pdf

Israeli studies:

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

<https://pubmed.ncbi.nlm.nih.gov/26800377/>

Cannabinoids for Behavioral Problems in Children With ASD (CBA)

<https://clinicaltrials.gov/ct2/show/NCT02956226>

Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study (P3.318)

https://n.neurology.org/content/90/15_Supplement/P3.318

Pharmaceutical CBD, and Medical Cannabis Reference list:

Artisanal CBD not as effective as pharmaceutical CBD for reducing seizures <https://www.sciencedaily.com/releases/2020/02/20200227160545.htm>

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000160/>

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial

<https://pubmed.ncbi.nlm.nih.gov/28576350/>

Cannabidiol (CBD) – what we know and what we don't <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>

Examining cannabidiol use in children <https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children>

Cannabinoids in Pediatrics <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/>

Pediatric cannabinoid Dosing Guidelines

<http://www.theroc.us/images/PediatricGuidelines.pdf>

"In general, the dose of CBD for a child is about 2.5 to 10 mg depending on their age, size, and symptom severity."

<https://dailycbd.com/en/cbd-children/>

Guanfacine Reference list:

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

<https://clinicaltrials.gov/ct2/show/NCT02048241>

Guanfacine in children with autism and/or intellectual disabilities

<https://pubmed.ncbi.nlm.nih.gov/18552703/>

Managing disruptive behavior in autism-spectrum disorder with guanfacine

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158025/>

Hallucinations associated with initiation of Guanfacine

[https://www.jaacap.org/article/S0890-8567\(09\)62120-1/pdf](https://www.jaacap.org/article/S0890-8567(09)62120-1/pdf)

General references:

Beside Oneself with Rage: The Doubled Self as Metaphor in a Narrative of Brain Injury with Emotional Dysregulation <https://link.springer.com/article/10.1007/s10912-018-9546-9>

Peaks and Troughs, Uneven Medication Coverage & ADHD. https://chadd.org/wp-content/uploads/2018/06/ATTN_Fall_17_PEAKS.pdf

Israeli studies:

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience

<https://pubmed.ncbi.nlm.nih.gov/26800377/>

Cannabinoids for Behavioral Problems in Children With ASD (CBA)

<https://clinicaltrials.gov/ct2/show/NCT02956226>

Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study (P3.318)

https://n.neurology.org/content/90/15_Supplement/P3.318

Pharmaceutical CBD, and Medical Cannabis Reference list:

Artisanal CBD not as effective as pharmaceutical CBD for reducing seizures <https://www.sciencedaily.com/releases/2020/02/20200227160545.htm>

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000160/>

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial

<https://pubmed.ncbi.nlm.nih.gov/28576350/>

Cannabidiol (CBD) – what we know and what we don't <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>

www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476

Examining cannabidiol use in children <https://www.contemporarypediatrics.com/view/examining-cannabidiol-use-children>

Cannabinoids in Pediatrics <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/>

Pediatric cannabinoid Dosing Guidelines

<http://www.theroc.us/images/PediatricGuidelines.pdf>

"In general, the dose of CBD for a child is about 2.5 to 10 mg depending on their age, size, and symptom severity."

<https://dailycbd.com/en/cbd-children/>

Guanfacine Reference list:

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

<https://clinicaltrials.gov/ct2/show/NCT02048241>

Guanfacine in children with autism and/or intellectual disabilities

<https://pubmed.ncbi.nlm.nih.gov/18552703/>

Managing disruptive behavior in autism-spectrum disorder with guanfacine

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158025/>

Hallucinations associated with initiation of Guanfacine

[https://www.jaacap.org/article/S0890-8567\(09\)62120-1/pdf](https://www.jaacap.org/article/S0890-8567(09)62120-1/pdf)

